Supplementary Material – PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States

<b>Supplementary Material</b>. PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States <i>Supplemental Table 1: ICD 09 and ICD 10 codes used for abstraction of patient comorbidities.</i> <i>Supplemental Table 2: comorbidities of included patients.</i> <i>Supplemental Figure 1: proportion of advanced HCC receiving PD-1 IMT according to US geography.</i> <i>Supplemental Figure 2: interaction analyses showing treatment effectiveness of PD-1 IMT versus no PD-1 IMT across patient subgroups. P-values were adjusted for multiplicity using the Bonferroni correction.</i>